UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Status:
RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.